Gurjeet Singh, MD
Neurology · Vancouver, WANPI 1780947937
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,387 of the $60,340 with a category attached, or 93.4%. 16 manufacturers reported payments, led by AbbVie at 45.1% of the total. Reporting peaked in 2021 at $30,676 and has fallen 50.6% since, to $15,142 in 2022. Among neurology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $290.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$27K
- SK Life Science, Inc.$16K
- UCB, Inc.$4K
- Biohaven Pharmaceuticals, Inc.$4K
- Neurelis, Inc.$3K
- Livanova USA, Inc.$2K
- plus $4K from 10 others
What the payments were for
- Consulting fees$6601%
- Speaking & faculty fees$56,38793%
- Travel & lodging$8271%
- Food & beverage$2,4464%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 100 | $27,210 |
| SK Life Science, Inc. | 21 | $15,521 |
| UCB, Inc. | 35 | $4,018 |
| Biohaven Pharmaceuticals, Inc. | 13 | $3,974 |
| Neurelis, Inc. | 3 | $3,428 |
| Livanova USA, Inc. | 10 | $2,473 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $1,754 |
| Eisai Inc. | 5 | $1,598 |
| Sunovion Pharmaceuticals Inc. | 6 | $139 |
| Medtronic | 1 | $69 |
| Greenwich Biosciences, Inc. | 2 | $54 |
| Lilly USA, LLC | 2 | $32 |
| AstraZeneca | 1 | $21 |
| GE HealthCare | 1 | $20 |
| Avion Pharmaceuticals | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$19,270
- XCOPRI$13,036
- NURTEC ODT$5,600
- BOTOX$4,904
- VALTOCO$3,428
- VNS Therapy$2,400
- Cenobamate$2,202
- QULIPTA$1,875
- Nayzilam$1,575
- Briviact$1,410
- Fycompa$1,250
- Dayvigo$285
How this compares
$60,340 in reported general payments places this provider in the 90th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 31 | $33,211 |
| Emgality PenGalcanezumab-Gnlm | 41 | $31,498 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $14,389 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 26 | $13,762 |
| RytaryCarbidopa/Levodopa | 11 | $7,584 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 111 | $4,340 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 54 | $3,479 |
| Levetiracetam | 116 | $2,685 |
| Lacosamide | 36 | $2,281 |
| Memantine Hcl | 39 | $952 |
| Oxcarbazepine | 12 | $893 |
| Zonisamide | 20 | $837 |
| Divalproex Sodium ErDivalproex Sodium | 41 | $830 |
| Donepezil Hcl | 87 | $744 |
| Gabapentin | 37 | $736 |
Paid to pharmacies, not to this prescriber.
Other neurology in Vancouver
- John DempsterVancouver$43K
- Pavle RepovicSeattle$1.1M
- Jason AldredSpokane$1M
- Pinky AgarwalKirkland$795K
- Stacy DonlonTacoma$613K
- Nathaniel WatsonSeattle$486K
- James BowenKirkland$379K
- Christyn EdmundsonSeattle$318K
- Jessica CraddockSpokane$266K
- Pravin KhemaniSeattle$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.